This reclassification questions the previous grouping of grade 3 and 4 astrocytomas as “high-grade,” given the distinct differences in molecular profiles and clinical outcomes between IDH mutant grade 3 astrocytomas and IDH-wild-type grade 4 glioblastomas [4]. This evidence concerns the gene IDH1 and glioblastoma.